Skip to main content
. 2015 May 1;10(5):e0126413. doi: 10.1371/journal.pone.0126413

Fig 2. The proportion of adverse drug reactions reported to the manufacturer within 2 weeks of onset.

Fig 2

(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride. Error bars represent the 95% confidence intervals.